metformin has been researched along with HIV-Associated Lipodystrophy Syndrome in 13 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
HIV-Associated Lipodystrophy Syndrome: Defective metabolism leading to fat maldistribution in patients infected with HIV. The etiology appears to be multifactorial and probably involves some combination of infection-induced alterations in metabolism, direct effects of antiretroviral therapy, and patient-related factors.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Metformin did not affect postprandial lipemia and could be used to treat insulin resistance in this population." | 5.15 | Differential effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy. ( Cabezas, MC; Dallinga-Thie, G; de Koning, EJ; Hoepelman, AI; Rabelink, TJ; van Wijk, JP, 2011) |
| "We conducted a randomized placebo-controlled trial to examine the effects of metformin on visceral adipose tissue (VAT), appendicular fat, lipid profile and insulin sensitivity in HIV-infected persons with central adiposity and mild insulin resistance." | 5.12 | A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy. ( Gorbach, S; Kohli, R; Shevitz, A; Wanke, C, 2007) |
| "Metformin use was associated with reduction of mean weight (-2." | 2.73 | Metformin increases HDL3-cholesterol and decreases subcutaneous truncal fat in nondiabetic patients with HIV-associated lipodystrophy. ( Barbosa, DS; Carrilho, AJ; De Faria, EC; Diehl, LA; Fabris, BA; Wiechmann, SL, 2008) |
| "Metformin was the only insulin-sensitizer to demonstrate beneficial effects on all three components of HALS." | 2.46 | The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. ( Larson, RJ; Sheth, SH, 2010) |
| "Metformin has shown some benefit in reducing VAT but at the expense of accelerating peripheral fat loss, and the thiazolidinediones have no effect on VAT." | 2.45 | Treatment options for HIV-associated central fat accumulation. ( Cofrancesco, J; Freedland, E; McComsey, G, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (76.92) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Paruthi, J | 1 |
| Gill, N | 1 |
| Mantzoros, CS | 1 |
| Fuller, J | 1 |
| Diehl, LA | 1 |
| Fabris, BA | 1 |
| Barbosa, DS | 1 |
| De Faria, EC | 1 |
| Wiechmann, SL | 1 |
| Carrilho, AJ | 1 |
| Cofrancesco, J | 1 |
| Freedland, E | 1 |
| McComsey, G | 1 |
| Sheth, SH | 1 |
| Larson, RJ | 1 |
| van Wijk, JP | 1 |
| Hoepelman, AI | 1 |
| de Koning, EJ | 1 |
| Dallinga-Thie, G | 1 |
| Rabelink, TJ | 1 |
| Cabezas, MC | 1 |
| Vigouroux, C | 1 |
| Martínez, E | 1 |
| Domingo, P | 1 |
| Ribera, E | 1 |
| Milinkovic, A | 1 |
| Arroyo, JA | 1 |
| Conget, I | 1 |
| Pérez-Cuevas, JB | 1 |
| Casamitjana, R | 1 |
| de Lazzari, E | 1 |
| Bianchi, L | 1 |
| Montserrat, E | 1 |
| Roca, M | 1 |
| Burgos, R | 1 |
| Arnaiz, JA | 1 |
| Gatell, JM | 1 |
| Benavides, S | 1 |
| Nahata, MC | 1 |
| Driscoll, SD | 1 |
| Meininger, GE | 1 |
| Lareau, MT | 1 |
| Dolan, SE | 1 |
| Killilea, KM | 1 |
| Hadigan, CM | 1 |
| Lloyd-Jones, DM | 1 |
| Klibanski, A | 1 |
| Frontera, WR | 1 |
| Grinspoon, SK | 1 |
| Martin, A | 1 |
| Mallon, PW | 1 |
| Kohli, R | 1 |
| Shevitz, A | 1 |
| Gorbach, S | 1 |
| Wanke, C | 1 |
| Bradbury, RA | 1 |
| Samaras, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Adiposity and Airway Inflammation in HIV-Associated Airway Disease[NCT02975258] | 102 participants (Actual) | Observational | 2015-09-30 | Completed | |||
| A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People With TB and Co-infected With HIV[NCT04930744] | Phase 2 | 112 participants (Anticipated) | Interventional | 2021-08-03 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for metformin and HIV-Associated Lipodystrophy Syndrome
| Article | Year |
|---|---|
Adipokines in the HIV/HAART-associated lipodystrophy syndrome.
Topics: Adiponectin; Glucose Intolerance; HIV-Associated Lipodystrophy Syndrome; Humans; Leptin; Metformin; | 2013 |
Treatment options for HIV-associated central fat accumulation.
Topics: Androgens; Anthropometry; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cardiovascular Dis | 2009 |
The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials.
Topics: Adult; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Insulin Resistanc | 2010 |
[Lipodystrophies: what treatment?].
Topics: Antiviral Agents; Diabetes Complications; Diabetes Mellitus; Diet; Exercise; HIV-Associated Lipodyst | 2003 |
Pharmacologic therapy for HIV-associated lipodystrophy.
Topics: Adipose Tissue; Contraindications; HIV-Associated Lipodystrophy Syndrome; Human Growth Hormone; Huma | 2004 |
Therapeutic approaches to combating lipoatrophy: do they work?
Topics: Antiretroviral Therapy, Highly Active; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans | 2005 |
Antiretroviral therapy and the human immunodeficiency virus--improved survival but at what cost?
Topics: Antiretroviral Therapy, Highly Active; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, | 2008 |
5 trials available for metformin and HIV-Associated Lipodystrophy Syndrome
| Article | Year |
|---|---|
Metformin increases HDL3-cholesterol and decreases subcutaneous truncal fat in nondiabetic patients with HIV-associated lipodystrophy.
Topics: Adolescent; Adult; Aged; Body Fat Distribution; Cholesterol, HDL; Female; HIV-Associated Lipodystrop | 2008 |
Differential effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy.
Topics: Area Under Curve; Biomarkers; Cholesterol; Fatty Acids, Nonesterified; HIV-Associated Lipodystrophy | 2011 |
Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors.
Topics: Adult; Antiretroviral Therapy, Highly Active; Body Constitution; Double-Blind Method; Female; Gemfib | 2003 |
Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients.
Topics: Adult; Blood Pressure; Body Composition; Cardiovascular Diseases; Combined Modality Therapy; Exercis | 2004 |
A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy.
Topics: Adipose Tissue; Adiposity; Adult; Area Under Curve; Female; HIV Infections; HIV-Associated Lipodystr | 2007 |
1 other study available for metformin and HIV-Associated Lipodystrophy Syndrome
| Article | Year |
|---|---|
A 39-year-old man with HIV-associated lipodystrophy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biocompatible Materials; Body Image; | 2008 |